whole-cell immunotherapy
BriaCell Advances Bria-MEL+ Melanoma Vaccine Toward the Clinic
BriaCell Therapeutics Corp. (TSX: BCT; Nasdaq: BCTX, BCTXL) announced on August 24, 2026, that its Bria-MEL+ personalized melanoma immunotherapy candidate reached a key genetic-engineering milestone. According to the company’s announcement, development activities are underway to support production for potential clinical use. Bria-MEL+ is a genetically modified, whole-cell cancer vaccine designed to activate both innate and…
